Oncolytics Biotech

Yahoo Finance • 27 days ago

Large-cap biotech is a sector to watch for investors: Analysts

Wall Street is looking for new ways to park cash in healthcare names, and large-cap biotechs have begun to gain steam. This asset class differs from traditional large-cap pharmaceutical companies — typically with a $200 billion market cap... Full story

Yahoo Finance • 2 months ago

Oncolytics Biotech announces voting results from annual meeting

SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), whose stock has delivered an impressive 56% return year-to-date according to InvestingPro data, reported Monday that shareholders elected all eight director nominees at its Annua... Full story

Yahoo Finance • 2 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and ex... Full story

Yahoo Finance • 2 months ago

Onc stock hits 52-week high at 309.25 USD

Onc stock reached a significant milestone, hitting a 52-week high of 309.25 USD. The $36.11 billion market cap company’s achievement reflects a robust performance over the past year, during which BeOne Medicines AG DRC, the company behind... Full story

Yahoo Finance • 2 months ago

Oncolytics Biotech regains compliance with Nasdaq listing requirements

SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a $34.64 billion market cap company, has regained compliance with Nasdaq’s minimum bid price requirement, according to a formal notice received Tuesday from the exchange’... Full story

Yahoo Finance • 2 months ago

Oncolytics Biotech reports positive biomarker data for pelareorep

SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage biotechnology company with a market capitalization of approximately $108 million, announced Wednesday that integrated biomarker analyses from multiple cl... Full story

Yahoo Finance • 3 months ago

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions... Full story

Yahoo Finance • 3 months ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

SAN DIEGO and CALGARY, Alberta, June 30, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as C... Full story

Yahoo Finance • 4 months ago

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organizati... Full story

Yahoo Finance • 8 months ago

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of diagnoses, with the aggressive nature of th... Full story

Yahoo Finance • 2 years ago

Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial If successful, new clinical study e... Full story

Yahoo Finance • 3 years ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Thursday, August 11, 2022, at 8:30 a.m. ET SAN DIEGO, CA and CALGARY, AB, July 27, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conferenc... Full story

Yahoo Finance • 3 years ago

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep's induced improvement in the prognosis... Full story

Yahoo Finance • 3 years ago

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Independent review identified, no safety concerns in trial's final safety run-in Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients... Full story